---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-23-000037"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:41:16.391525+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Selecta licenses Xork IgG protease to Astellas for up to $340M plus royalties for Pompe disease

## Summary
- Licenses Xork to Astellas for $10M upfront, up to $340M in milestones plus royalties on sales for Pompe disease.
- Phase 3 DISSOLVE I & II topline data for SEL-212 in chronic refractory gout expected in Q1 2023.
- Selected IL-2 development candidate to combine with ImmTOR for autoimmune diseases; IND-enabling studies planned in 2023.
- Initiated Phase 1/2 ReiMMAgine trial of SEL-302 (AAV gene therapy + ImmTOR) for methylmalonic acidemia.

## SEC filing metadata
- accession: 0001453687-23-000037
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/0001453687-23-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/selb-20230104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-23-000037
- JSON: https://secwatch.observer/filing/0001453687-23-000037.json
- Plain text: https://secwatch.observer/filing/0001453687-23-000037.txt

## Key facts
- Executive change
  Göran A. Ando retired as Director at Cartesian Therapeutics, Inc..
  - Action: retired
  - Role: Director
  source text: On January 4, 2023, Göran A. Ando, M.D., a member of the Board of Directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”), notified the Company that he is retiring from the Company’s Board effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368723000037/0001453687-23-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.